Sachi Bioworks wins Phase I NASA SBIR grant

Updated: Nov 17


March 25th, 2021



Sachi Bioworks will be working with NASA to develop novel therapeutics for radiation countermeasures for deployment in space travel. This will be part of broader Sachi portfolio for Space medicine, carcinogenesis, and radiation countermeasures for the growing space industry.



“The future of Space travel will depend on our ability to provide radiation countermeasure to protect our astronauts.”

Reversing Immune Dysregulation During Spaceflight Missions


This partnership will result in rapid development of radiation countermeasures (single targets for first-in-class, and combination targets for best-in-class) for deployment in deep-space missions. These will be developed using our proprietary platform for high-throughput, rapid, and targeted gene manipulation (reversible) of immune and other hematopoietic proteins, to utilize our own body to create these protective enzymes to counter and repair the damage caused by deep space radiation.

In long space exploration missions, astronauts are subjected to increased amounts of radiation exposure, which can lead to Acute Radiation Syndrome (ARS).

While specific haemopoietic protein variants have been used as medical countermeasures (MCM) for ARS, several recent studies have identified need for inclusion of other targets to provide more effective radiation-exposure treatment. Recent multi-omics studies and radiobiological insights have also provided new gene targets to act as radiation MCM. Using a range of different proteins poses significant challenges and associated logistical challenges in their safe transportation and storage during space travel. Existing genetic manipulation methods are laborious, expensive, and inefficient. We address this market and technology void using our proprietary platform technology that can target and regulate expression of desired genes.




67 views0 comments

Recent Posts

See All